# Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct07669467/  
OnCo record `nct07669467` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nuvastatic 300 in triple-negative breast cancer, run by Natureceuticals Sdn Bhd, now recruiting.

## Summary

Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT07669467 by Natureceuticals Sdn Bhd, with 250 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: Nuvastatic 300 and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07669467
- Phase: 3
- Setting: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300 mg Capsules in Reducing Chemotherapy-Induced Fatigue in Patients With Metastatic Triple-Negative Breast Cancer Receiving Standard Chemotherapy
- Sponsor: Natureceuticals Sdn Bhd
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT07669467: https://clinicaltrials.gov/study/NCT07669467

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)

---
JSON: https://onco.cc/api/v1/entities/nct07669467.json